Q2 2026 saw 13% reported sales growth and 4.8% comparable growth, with adjusted EPS up 4% year-over-year. Full-year adjusted EPS guidance was raised, and strong performance was noted in diagnostics and medical devices, while nutrition declined.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.